Full-Time
Updated on 8/20/2026
Pharma: treats addiction and mental illness
$88k - $95.7k/yr
Raleigh, NC, USA
In Person
Bachelor's
See people who can refer or advise you
Indivior focuses on developing medicines for substance use disorders and serious mental illnesses. Its products are prescription pharmaceutical treatments, brought to market after research and development, and sold through healthcare professionals to patients worldwide. The company’s approach centers on patient safety, with ongoing monitoring and reporting of adverse events to ensure high-quality therapies. Compared with competitors, Indivior emphasizes targeted medicines for addiction and mental health, combining scientific R&D with a global commercialization presence to address critical healthcare needs. Its goal is to create sustainable value by improving patient outcomes and addressing unmet medical needs in global health.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Bon Air, Virginia
Founded
2014
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Paid Vacation
Paid Holidays
Paid Sick Leave
Flexible Work Hours
Remote Work Options
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Adoption Assistance
Tuition Reimbursement
Employee Stock Purchase Plan
401(k) Company Match
Profit Sharing
Legal Services
Pet Insurance
Gym Membership
BizWire Express - Bringing you the latest news as it happens from all over the world.
Supernus and Indivior agree to an all-stock merger. Indivior plans a $1 billion special dividend before closing, with the combined company set to trade as SUPN and target $125 million in annual cost savings. about 1 hour ago - 1 min What's going on here? Supernus Pharmaceuticals and Indivior said Monday they'll merge in a tax-free, all-stock deal, but Indivior plans to send shareholders a $1 billion special dividend before the tie-up closes in Q4. What does this mean? Both boards have unanimously approved the merger, which values the combined company around scale and efficiency rather than a simple cash takeover. Under the terms, Supernus shareholders will receive 1.5401 Indivior shares per Supernus share, leaving Indivior owners with about 56.5% of the new business. Indivior will also pay a one-time $1 billion dividend before closing, partly funded by a new $650 million term loan - a way to return cash now w... Keep reading for free. This content is free, but you must be logged in to continue reading. Already have an account?
Supernus Pharmaceuticals reported total revenues of $219.1 million for Q2 2026, up 32% year-over-year. Combined revenues from the company's four growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—reached $175.7 million, marking a 52% increase compared to Q2 2025. ONAPGO generated $13.5 million in net product sales during the quarter. Since launching in April 2025, the product has attracted approximately 2,600 enrollment forms from around 720 prescribers through end-July 2026. ZURZUVAE collaboration revenue totalled $35.4 million in Q2 2026, representing 50% of Biogen's net revenues for the product. US sales of ZURZUVAE increased approximately 53% year-over-year. Supernus raised its full-year 2026 financial guidance and announced a merger agreement with Indivior Pharmaceuticals to create a diversified CNS biopharmaceutical company.
Supernus Pharmaceuticals Q2 2026 Earnings & Major Merger Announcement
Indivior Pharmaceuticals' Chief Scientific Officer Christian Heidbreder sold 18,586 shares in an open-market transaction on 11 June 2026 at $38.06 per share, according to an SEC Form 4 filing. The sale represented 7.54% of his direct holdings. Following the transaction, Heidbreder retains 227,923 shares valued at approximately $8.69 million, maintaining a 0.18% ownership stake in the company. The sale occurred after Indivior's shares delivered a 177% one-year total return, rising from a 52-week low of $13.45 to reach $41 in May. Indivior develops buprenorphine-based medications for opioid dependence treatment, including Suboxone Film and Subutex Tablet. The company reported $1.29 billion in trailing twelve-month revenue and $252 million in net income.